{"body": "Is daridorexant effective for insomnia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36473030", "http://www.ncbi.nlm.nih.gov/pubmed/35298826"], "ideal_answer": ["Yes. Daridorexant an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia."], "exact_answer": "yes", "type": "yesno", "id": "64041e97201352f04a00001e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 1224, "text": "Daridorexant was superior to placebo in reducing wake time after sleep onset (MD = -13.26; 95% CI, -15.48 to -11.03; P < 0.00001), latency to persistent sleep (MD = -7.23; 95% CI, -9.60 to -4.85; P < 0.00001), with increasing the total sleep time (MD = 14.80; 95% CI, 11.18-18.42; P < 0.00001) and subjective total sleep time (MD = 14.80; 95% CI, 11.18-18.42], P < 0.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR) = 1.19; 95% CI, 1.05-1.35;, P = 0.005], specifically somnolence (RR = 1.19; 95% CI, 1.13-3.23; P = 0.005) and fatigue (RR = 2.01; 95% CI, 1.21-3.36; P = 0.007). Daridorexant is superior to placebo in improving sleep quality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030", "endSection": "abstract"}]}
{"body": "Are histone deacetylase (HDAC) inhibitors good candidates to control metastasis of solid tumors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19417021", "http://www.ncbi.nlm.nih.gov/pubmed/20884621", "http://www.ncbi.nlm.nih.gov/pubmed/22279574", "http://www.ncbi.nlm.nih.gov/pubmed/21041383", "http://www.ncbi.nlm.nih.gov/pubmed/22038994", "http://www.ncbi.nlm.nih.gov/pubmed/22811583", "http://www.ncbi.nlm.nih.gov/pubmed/10893438", "http://www.ncbi.nlm.nih.gov/pubmed/15800932", "http://www.ncbi.nlm.nih.gov/pubmed/21452015", "http://www.ncbi.nlm.nih.gov/pubmed/19861438", "http://www.ncbi.nlm.nih.gov/pubmed/19789319", "http://www.ncbi.nlm.nih.gov/pubmed/19509253", "http://www.ncbi.nlm.nih.gov/pubmed/18981013", "http://www.ncbi.nlm.nih.gov/pubmed/22161747", "http://www.ncbi.nlm.nih.gov/pubmed/18506586", "http://www.ncbi.nlm.nih.gov/pubmed/15318170"], "ideal_answer": ["Yes, some HDAC inhibitors, such as Vorinostat, are on trial for human treatment after proving successful in animal models. Combination with other drugs is likely to be needed to control metastasis."], "exact_answer": "yes", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056572"], "type": "yesno", "id": "517404878ed59a060a000023", "snippets": [{"offsetInBeginSection": 1227, "offsetInEndSection": 1375, "text": "JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19861438", "endSection": "sections.0"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1722, "text": "Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18981013", "endSection": "sections.0"}, {"offsetInBeginSection": 1518, "offsetInEndSection": 1832, "text": "Treatments of different structural classes of HDACi simultaneously induced cell death and promoted cell migration and metastasis in multiple cancer cell types. Suppression of HDACi-induced PKCs leads to development of low toxic and long-term therapeutic strategies to potentially treat cancer as a chronic disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811583", "endSection": "sections.0"}, {"offsetInBeginSection": 1396, "offsetInEndSection": 1665, "text": "mRNA expression analysis of lung tumor bearing mice suggested that the enhanced chemopreventive activity of the combination is related to atorvastatin modulation of DNA repair, SAHA modulation of angiogenesis, and both drugs modulating invasion and metastasis pathways.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161747", "endSection": "sections.0"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1268, "text": "Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells. VPA inhibited the growth of UM tumors in vivo.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038994", "endSection": "sections.0"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1422, "text": "When both drugs were used in concert additive effects were observed on the migratory and invasive behavior but not on tumor-endothelium and tumor-matrix interaction. Separate mTOR or HDAC inhibition slows processes related to tumor metastasis. The RAD001-VPA combination showed advantage over VPA monotreatment with particular respect to migration and invasion.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21452015", "endSection": "sections.0"}, {"offsetInBeginSection": 1555, "offsetInEndSection": 1793, "text": "In conclusion, sequential treatments of mice with MS-275 followed by TRAIL may target multiple pathways to reverse EMT and inhibit tumor progression, angiogenesis, and metastasis and represent a novel therapeutic approach to treat cancer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041383", "endSection": "sections.0"}, {"offsetInBeginSection": 1345, "offsetInEndSection": 1425, "text": "In vivo, AA98 synergized with vorinostat to inhibit tumor growth and metastasis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20884621", "endSection": "sections.0"}, {"offsetInBeginSection": 1440, "offsetInEndSection": 1782, "text": "We report the first preclinical data for the prevention of brain metastasis of triple-negative breast cancer. Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%. Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789319", "endSection": "sections.0"}, {"offsetInBeginSection": 1483, "offsetInEndSection": 1616, "text": "Combining vorinostat with radiation may be a potential treatment option for patients with breast cancer who develop brain metastases.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509253", "endSection": "sections.0"}, {"offsetInBeginSection": 1604, "offsetInEndSection": 1748, "text": "Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was observed when combined with chemotherapy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417021", "endSection": "sections.0"}, {"offsetInBeginSection": 1042, "offsetInEndSection": 1367, "text": "In a 4T1 metastatic breast carcinoma model, AN-7 inhibited the formation of lung lesions by 76% and AN-9 by 47%, further demonstrating the greater efficacy of AN-7 compared to AN-9 (P<0.02). Both AN-7 and AN-9 exhibited antimetastatic and antiangiogenic activities by reducing vascularization, bFGF expression and HIF-1alpha.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506586", "endSection": "sections.0"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1507, "text": "Since prolonged oral administration with 50 mg/kg or a single oral dose of 1.2 g/kg AN-7 did not cause adverse effects and the former exhibited significant anticancer activity, AN-7 is likely to display a high therapeutic index and may be beneficial for prostate cancer patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800932", "endSection": "sections.0"}, {"offsetInBeginSection": 435, "offsetInEndSection": 801, "text": "We show that apicidin significantly inhibits H-ras-induced invasive phenotype of MCF10A human breast epithelial cells in parallel with a specific downregulation of matrix metalloproteinase (MMP)-2, but not MMP-9. We also show that apicidin induces a morphological reversal and growth inhibition of H-ras MCF10A cells similar to that induced by other HDAC inhibitors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10893438", "endSection": "sections.0"}, {"offsetInBeginSection": 1397, "offsetInEndSection": 1553, "text": "We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318170", "endSection": "sections.0"}]}
{"body": "Is the abnormal dosage of ultraconserved elements disfavored in cancer cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25340765"], "ideal_answer": ["No. Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."], "exact_answer": "no", "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:162"], "type": "yesno", "id": "56c0708eef6e39474100001f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "title"}, {"offsetInBeginSection": 294, "offsetInEndSection": 1335, "text": "We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs. In striking contrast, CNVs arising specifically in cancer cells are, as a rule, not depleted for UCEs and can even become significantly enriched. This observation raises the possibility that CNVs that arise somatically and are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state. In support of this latter explanation, somatic CNVs that are not associated with disease are depleted for UCEs. Finally, we show that it is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time, suggesting that depletion may be established through selection against UCE-disrupting CNVs without the requirement for meiotic divisions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 864, "offsetInEndSection": 954, "text": "Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}]}
{"body": "Has the gorilla genome been determined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11592477", "http://www.ncbi.nlm.nih.gov/pubmed/27034376", "http://www.ncbi.nlm.nih.gov/pubmed/22398555", "http://www.ncbi.nlm.nih.gov/pubmed/27435933"], "ideal_answer": ["Yes, the gorilla genome has been sequenced."], "exact_answer": "yes", "type": "yesno", "id": "58dfec676fddd3e83e000006", "snippets": [{"offsetInBeginSection": 494, "offsetInEndSection": 638, "text": "Starting with human, chimpanzee, gorilla, and orangutan genomes, our software generated an exhaustive data set of 292 ALs (∼1 kb each) in ∼3 h. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435933", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 258, "text": "We generated a high-quality assembly of the gorilla genome using single-molecule, real-time sequence technology and a string graph de novo assembly algorithm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034376", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 301, "text": "Here we present the assembly and analysis of a genome sequence for the western lowland gorilla, and compare the whole genomes of all extant great ape genera.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22398555", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "DNA sequencing reveals that the genomes of the human, gorilla and chimpanzee share more than 98% homology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592477", "endSection": "abstract"}]}
{"body": "Is rucaparib used for ovarian cancer treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24962512", "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "http://www.ncbi.nlm.nih.gov/pubmed/26281686", "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "http://www.ncbi.nlm.nih.gov/pubmed/27702817", "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "http://www.ncbi.nlm.nih.gov/pubmed/27022037", "http://www.ncbi.nlm.nih.gov/pubmed/23729402"], "ideal_answer": ["Yes, rucaparib is a PARP inhibitor that is used for ovarian cancer treatment."], "exact_answer": "yes", "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "http://www.disease-ontology.org/api/metadata/DOID:2394", "http://www.disease-ontology.org/api/metadata/DOID:4001", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024221"], "type": "yesno", "id": "588485bbe56acf517600000b", "snippets": [{"offsetInBeginSection": 1323, "offsetInEndSection": 1607, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1359, "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "endSection": "abstract"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1840, "text": "IMPLICATIONS FOR PRACTICE: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has recently received approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with a second agent (rucaparib) likely to be approved in the near future.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27022037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702817", "endSection": "title"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1413, "text": "There are a number of other PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib, niraparib, veliparib, and talazoparib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "endSection": "title"}, {"offsetInBeginSection": 3353, "offsetInEndSection": 3757, "text": "INTERPRETATION: In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas. Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 1317, "offsetInEndSection": 1600, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 1596, "offsetInEndSection": 1762, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 501, "offsetInEndSection": 704, "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1771, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 650, "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.RESULTS: In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1805, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>©2013 AACR</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 619, "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1606, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 570, "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1806, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>©2013 AACR</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1329, "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 707, "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1772, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}]}
{"body": "Is cardiac magnetic resonance imaging indicated in the pre-participation screening of athletes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22375189", "http://www.ncbi.nlm.nih.gov/pubmed/21567995", "http://www.ncbi.nlm.nih.gov/pubmed/22375228", "http://www.ncbi.nlm.nih.gov/pubmed/22653640", "http://www.ncbi.nlm.nih.gov/pubmed/19734502", "http://www.ncbi.nlm.nih.gov/pubmed/16914373", "http://www.ncbi.nlm.nih.gov/pubmed/16831826", "http://www.ncbi.nlm.nih.gov/pubmed/21118665", "http://www.ncbi.nlm.nih.gov/pubmed/10663764", "http://www.ncbi.nlm.nih.gov/pubmed/19055989", "http://www.ncbi.nlm.nih.gov/pubmed/24029371", "http://www.ncbi.nlm.nih.gov/pubmed/20048491", "http://www.ncbi.nlm.nih.gov/pubmed/23097483", "http://www.ncbi.nlm.nih.gov/pubmed/15689345", "http://www.ncbi.nlm.nih.gov/pubmed/18325444", "http://www.ncbi.nlm.nih.gov/pubmed/22983606", "http://www.ncbi.nlm.nih.gov/pubmed/22853772", "http://www.ncbi.nlm.nih.gov/pubmed/16004915", "http://www.ncbi.nlm.nih.gov/pubmed/15166900", "http://www.ncbi.nlm.nih.gov/pubmed/12446071", "http://www.ncbi.nlm.nih.gov/pubmed/21791458", "http://www.ncbi.nlm.nih.gov/pubmed/23897528", "http://www.ncbi.nlm.nih.gov/pubmed/21278396", "http://www.ncbi.nlm.nih.gov/pubmed/20833588", "http://www.ncbi.nlm.nih.gov/pubmed/20599016", "http://www.ncbi.nlm.nih.gov/pubmed/18208827", "http://www.ncbi.nlm.nih.gov/pubmed/21782775", "http://www.ncbi.nlm.nih.gov/pubmed/20705486", "http://www.ncbi.nlm.nih.gov/pubmed/21486912", "http://www.ncbi.nlm.nih.gov/pubmed/22457200"], "ideal_answer": ["Currently cardiac magnetic resonance imaging is not indicated in the pre-participation screening of athletes. However the potential of this imaging technique to provide new information on cardiac function morphology and myocardial composition, in particular with regard to myocardial fibrosis, gets it potentially suitable to be applied in the pre-participation screening of athletes"], "exact_answer": "no", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019028", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054874", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008279", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013177", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352"], "type": "yesno", "id": "531d3dc0267d7dd053000005", "snippets": [{"offsetInBeginSection": 1858, "offsetInEndSection": 2112, "text": "As modern imaging further enhances our understanding of the spectrum of athlete's heart, its role may expand from the assessment of athletes with suspected disease to being part of comprehensive pre-participation screening in apparently healthy athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029371", "endSection": "abstract"}, {"offsetInBeginSection": 801, "offsetInEndSection": 872, "text": "Finally we will address the role of CMR in pre-participation screening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097483", "endSection": "abstract"}]}
{"body": "During which stage of the cell cycle is cohesin deposited on the yeast genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11069892", "http://www.ncbi.nlm.nih.gov/pubmed/17670945", "http://www.ncbi.nlm.nih.gov/pubmed/15870297", "http://www.ncbi.nlm.nih.gov/pubmed/24778232", "http://www.ncbi.nlm.nih.gov/pubmed/18178375", "http://www.ncbi.nlm.nih.gov/pubmed/11081625", "http://www.ncbi.nlm.nih.gov/pubmed/15137940", "http://www.ncbi.nlm.nih.gov/pubmed/15309048", "http://www.ncbi.nlm.nih.gov/pubmed/18079700", "http://www.ncbi.nlm.nih.gov/pubmed/9990856", "http://www.ncbi.nlm.nih.gov/pubmed/22677545"], "ideal_answer": ["In the budding yeast, cohesin is loaded onto the chromosome during the late G1 phase, establishes sister chromatid cohesion concomitant with DNA replication, and dissociates by the telophase.", "In the budding yeast, cohesin is loaded onto the chromosome during the late G1 phase, establishes sister chromatid cohesion concomitant with DNA replication, and dissociates by the telophase. ", "Cohesin association with G1 chromosomes requires continued activity of the cohesin loader Mis4/Ssl3, suggesting that repeated loading cycles maintain cohesin binding. In mammalian cells, cohesin binding to chromatin is dynamic in G1, but becomes stabilized during S-phase. Instead, we find that cohesin stability increases at the time of S-phase in a reaction that can be uncoupled from DNA replication. Budding yeast Scc1p/Mcd1p, an essential subunit, is cleaved and dissociates from chromosomes in anaphase, leading to sister chromatid separation."], "exact_answer": ["S-phase"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002453", "http://amigo.geneontology.org/amigo/term/GO:0007049"], "type": "factoid", "id": "56e2acfe51531f7e33000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "In the budding yeast, cohesin is loaded onto the chromosome during the late G1 phase, establishes sister chromatid cohesion concomitant with DNA replication, and dissociates by the telophase. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18178375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Sister chromatid cohesion is mediated by cohesin, but the process of cohesion establishment during S-phase is still enigmatic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079700", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1022, "text": "Instead, we find that cohesin stability increases at the time of S-phase in a reaction that can be uncoupled from DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079700", "endSection": "abstract"}, {"offsetInBeginSection": 424, "offsetInEndSection": 607, "text": "By using \"single-copy\" derivatives of the 2-microm plasmid, we demonstrate that recruitment of cohesin at STB during S phase indeed translates into cohesion between plasmid molecules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17670945", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 992, "text": "In cells recovering from nocodazole-induced spindle depolymerization and G(2)/M arrest, cohesin-STB association can be established coincident with spindle restoration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15870297", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1076, "text": "This postreplication recruitment of cohesin is not functional in equipartitioning. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15870297", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 325, "text": "We have used chromatin immunoprecipitation coupled with microarray analysis (ChIP chip) to produce a genome-wide description of cohesin binding to meiotic and mitotic chromosomes of Saccharomyces cerevisiae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15309048", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 623, "text": "Cohesin sites are highly conserved in meiosis and mitosis, suggesting that chromosomes share a common underlying structure during different developmental programs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15309048", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Cohesin complex acts in the formation and maintenance of sister chromatid cohesion during and after S phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11069892", "endSection": "abstract"}, {"offsetInBeginSection": 378, "offsetInEndSection": 561, "text": " Proteolytic cleavage of cohesin's Sccl subunit at the metaphase to anaphase transition is essential for sister chromatid separation and depends on a conserved protein called separin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11081625", "endSection": "abstract"}, {"offsetInBeginSection": 549, "offsetInEndSection": 705, "text": "Four of these proteins, Scc1p, Scc3p, Smc1p, and Smc3p, are subunits of a 'Cohesin' complex that binds chromosomes from late G1 until the onset of anaphase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9990856", "endSection": "abstract"}, {"offsetInBeginSection": 894, "offsetInEndSection": 1018, "text": "It is necessary for the establishment of cohesion during DNA replication but not for its maintenance during G2 and M phases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9990856", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 501, "text": "Here, we show that cohesin destruction in metaphase is sufficient for segregation of much of the budding yeast genome, but not of the long arm of chromosome XII that contains the rDNA repeats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15137940", "endSection": "abstract"}, {"offsetInBeginSection": 1295, "offsetInEndSection": 1668, "text": "In this review, we have discussed the life cycle of cohesin during both mitotic and meiotic cell divisions including the structure and architecture of cohesin complex, relevance of cohesin associated proteins, mechanism of cohesin loading onto the chromatin, cohesion establishment and the mechanism of cohesin disassembly during anaphase to separate the sister chromatids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677545", "endSection": "abstract"}, {"offsetInBeginSection": 589, "offsetInEndSection": 755, "text": "Cohesin association with G1 chromosomes requires continued activity of the cohesin loader Mis4/Ssl3, suggesting that repeated loading cycles maintain cohesin binding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079700", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Cdc14 phosphatase induces rDNA condensation and resolves cohesin-independent cohesion during budding yeast anaphase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15137940", "endSection": "title"}, {"offsetInBeginSection": 152, "offsetInEndSection": 658, "text": "Cohesins are deposited by a conserved heterodimeric loading complex composed of the Scc2 and Scc4 proteins in Saccharomyces cerevisiae, but how the Scc2/Scc4 deposition complex regulates the spatiotemporal association of cohesin with chromosomes is not understood. We examined Scc2 chromatin association during the cell division cycle and found that the affinity of Scc2 for chromatin increases biphasically during the cell cycle, increasing first transiently in late G1 phase and then again later in G2/M.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778232", "endSection": "abstract"}]}
{"body": "What is the estimated cost reduction when using telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26785833"], "ideal_answer": ["The estimated cost reduction by online counseling is about 10-12%."], "exact_answer": ["10-12%"], "type": "factoid", "id": "6415bb3c690f196b5100000e", "snippets": [{"offsetInBeginSection": 1548, "offsetInEndSection": 1644, "text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "endSection": "abstract"}]}
{"body": "How can the fetal Rhesus be determined with non-invasive testing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25380024", "http://www.ncbi.nlm.nih.gov/pubmed/21244652", "http://www.ncbi.nlm.nih.gov/pubmed/21686347", "http://www.ncbi.nlm.nih.gov/pubmed/20938838", "http://www.ncbi.nlm.nih.gov/pubmed/10985940", "http://www.ncbi.nlm.nih.gov/pubmed/24204719", "http://www.ncbi.nlm.nih.gov/pubmed/22386678", "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "http://www.ncbi.nlm.nih.gov/pubmed/26140187", "http://www.ncbi.nlm.nih.gov/pubmed/24786470", "http://www.ncbi.nlm.nih.gov/pubmed/21075065", "http://www.ncbi.nlm.nih.gov/pubmed/18751991", "http://www.ncbi.nlm.nih.gov/pubmed/26259290", "http://www.ncbi.nlm.nih.gov/pubmed/21576416", "http://www.ncbi.nlm.nih.gov/pubmed/23024794", "http://www.ncbi.nlm.nih.gov/pubmed/18945714", "http://www.ncbi.nlm.nih.gov/pubmed/23072857", "http://www.ncbi.nlm.nih.gov/pubmed/15980640", "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "http://www.ncbi.nlm.nih.gov/pubmed/20482298", "http://www.ncbi.nlm.nih.gov/pubmed/10519426"], "ideal_answer": ["The detection of fetal RhD status can be achieved with the non-invasive method of assessing free fetal DNA in the maternal blood."], "exact_answer": ["free fetal DNA from maternal cirulcation"], "type": "factoid", "id": "571366ba1174fb1755000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Determination of fetal rhesus d status by maternal plasma DNA analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DNA(cffDNA) extracted from plasma samples of Rhesus (Rh) D-negative pregnant women by using real-time polymerase chain reaction (PCR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1172, "text": "Performing real-time PCR on cffDNA showed accurate, efficient and reliable results, allowing rapid and high throughput non invasive determination of fetal sex and RhD status in clinical samples", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Non-invasive prenatal diagnosis of fetal RhD by using free fetal DNA", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "title"}, {"offsetInBeginSection": 138, "offsetInEndSection": 311, "text": "The aim of this study is to determine fetal RhD status in the Rh incompatible pregnancies with an non-invasive technique; free fetal DNA isolation from maternal circulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "abstract"}, {"offsetInBeginSection": 1057, "offsetInEndSection": 1405, "text": " The detection of fetal RhD status by using a non-invasive method from maternal circulation was found to be possible. Assessing fetal RhD status non-invasively by using free fetal DNA in maternal blood will be cost-efficient, avoiding unnecessary indirect Coombs test and unnecessary Rhogam applications that is used in RH incompatible pregnancies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "abstract"}, {"offsetInBeginSection": 1133, "offsetInEndSection": 1411, "text": "Fruitful research efforts have resulted in the clinical implementation of a number of non-invasive prenatal tests based on maternal plasma DNA analysis and included tests for fetal sex assessment, fetal rhesus D blood group genotyping and fetal chromosomal aneuploidy detection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Non-invasive antenatal diagnosis of fetal rhesus status in an alloimmunised patient.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21686347", "endSection": "title"}, {"offsetInBeginSection": 1793, "offsetInEndSection": 2230, "text": "Our subsequent investigations have shown that this elevation in fetal cell traffic may serve as an early marker for those pregnancies at risk for this disorder.A very recent exciting discovery has been that free extracellular fetal DNA can be detected in the plasma and serum of pregnant women, which may permit the rapid and accurate detection of uniquely fetal loci, such as the fetal rhesus D gene in rhesus D negative pregnant women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10985940", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Fetal rhesus D (RhD) status determination using circulating cell-free fetal DNA from maternal plasma or serum is now recognized in Europe as a reliable and useful tool.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22386678", "endSection": "abstract"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1222, "text": "NGS is now sufficiently sensitive to analyze circulating fetal DNA in maternal blood (cell-free fetal DNA, cffDNA), enabling applications such as non invasive diagnosis of fetal sex (and X-linked diseases), fetal rhesus among rhesus-negative women, trisomy and, in the near future, Mendelian mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259290", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometry", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18751991", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Non-invasive RNA-based determination of fetal Rhesus D type: a prospective study based on 96 pregnancies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10519426", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "BACKGROUND: Analysis of cell free fetal (cff) DNA in maternal plasma is used routinely for non invasive prenatal diagnosis (NIPD) of fetal sex determination, fetal rhesus D status and some single gene disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024794", "endSection": "abstract"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1140, "text": "Fruitful research efforts have resulted in the clinical implementation of a number of non-invasive prenatal tests based on maternal plasma DNA analysis and included tests for fetal sex assessment, fetal rhesus D blood group genotyping and fetal chromosomal aneuploidy detection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": " Non-invasive prenatal diagnosis and testing by analysis of cell-free DNA in the maternal circulation is a rapidly evolving field. Current clinical applications include fetal sex determination, fetal rhesus D determination, the diagnosis of some single gene disorders, and a highly accurate screening test for aneuploidies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24786470", "endSection": "abstract"}]}
{"body": "Which tool has been developed to discover VNTR-associated deletions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34864893"], "ideal_answer": ["Τrfermikit is a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. In such regions, it achieves a better trade-off between sensitivity and false discovery than a state-of-the-art structural variation (SV) caller, Manta, and complements it by recovering a significant number of deletions that Manta missed. trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment."], "exact_answer": ["trfermikit"], "type": "factoid", "id": "621911323a8413c653000038", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "trfermikit: a tool to discover VNTR-associated deletions.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 582, "text": "We present trfermikit, a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. In such regions, it achieves a better trade-off between sensitivity and false discovery than a state-of-the-art structural variation (SV) caller, Manta, and complements it by recovering a significant number of deletions that Manta missed. trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 584, "text": "trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment.AV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequenci", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893", "endSection": "abstract"}]}
{"body": "What is the chromosomal abnormality associated with Klinefelter Syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8203057", "http://www.ncbi.nlm.nih.gov/pubmed/14018845", "http://www.ncbi.nlm.nih.gov/pubmed/17932453", "http://www.ncbi.nlm.nih.gov/pubmed/20172548", "http://www.ncbi.nlm.nih.gov/pubmed/6178494", "http://www.ncbi.nlm.nih.gov/pubmed/28275551", "http://www.ncbi.nlm.nih.gov/pubmed/27408358", "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "http://www.ncbi.nlm.nih.gov/pubmed/29423966", "http://www.ncbi.nlm.nih.gov/pubmed/25973391", "http://www.ncbi.nlm.nih.gov/pubmed/31916730", "http://www.ncbi.nlm.nih.gov/pubmed/30127341", "http://www.ncbi.nlm.nih.gov/pubmed/28782868", "http://www.ncbi.nlm.nih.gov/pubmed/16529294", "http://www.ncbi.nlm.nih.gov/pubmed/22486321", "http://www.ncbi.nlm.nih.gov/pubmed/29665107", "http://www.ncbi.nlm.nih.gov/pubmed/29406610", "http://www.ncbi.nlm.nih.gov/pubmed/17077438"], "ideal_answer": ["About 1 in 650 boys are born with an extra X chromosome (47,XXY or Klinefelter syndrome). 47,XXY", "About 1 in 650 boys are born with an extra X chromosome (47,XXY or Klinefelter syndrome)"], "exact_answer": ["XXY"], "type": "factoid", "id": "5e669e0e1af46fc130000019", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 106, "text": "Klinefelter's syndrome is a sex chromosome abnormality affecting approximately 1 in 1000 men. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28782868", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1035, "text": "Klinefelter syndrome (XXY)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "About 1 in 650 boys are born with an extra X chromosome (47,XXY or Klinefelter syndrome). 47,XXY", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29406610", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 448, "text": "On the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932453", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 305, "text": "The formal cytogenetic designation for Klinefelter syndrome is 47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 382, "text": "Klinefelter syndrome (KS) is characterized by an additional X chromosome in males leading to a karyotype of 47,XXY.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31916730", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Klinefelter syndrome (KS), a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date. We p", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973391", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 308, "text": " formal cytogenetic designation for Klinefelter syndrome is 47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction. In", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "A case of Klinefelter's syndrome with the development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY chromosomal abnormality may be more than coincidental.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6178494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY karyotype associated with hypogonadism and infertility. W", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28275551", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 443, "text": "ed. The most common cytogenetic defects associated with nonobstructive azoospermia are numerical and structural chromosome abnormalities, including Klinefelter syndrome (47,XXY) and Y chromosome microdeletions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20172548", "endSection": "abstract"}, {"offsetInBeginSection": 455, "offsetInEndSection": 609, "text": "alysis showed azoospermia, and chromosomal analysis revealed a 47,XY,i(X)(q10) karyotype, which is a rare variant of Klinefelter syndrome. No spermatozoon", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29665107", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 457, "text": "the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular dysfunction. Here, we", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932453", "endSection": "abstract"}, {"offsetInBeginSection": 633, "offsetInEndSection": 798, "text": "8 patients, 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY) was the most common chromosomal aberration. The incidenc", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16529294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY karyotype associated with hypogonadism and infertility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27408358", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 399, "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY, XXYY, XXXY and XXXXY.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14018845", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Klinefelter's syndrome, characterised by a 47,XXY chromosomal pattern, has largely been associated with physical abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17077438", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Klinefelter syndrome associated with 13/14 translocation abnormality 46,XXY,t(13q;14q).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8203057", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Klinefelter syndrome is caused by the presence of one or more additional X chromosomes in an affected male.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22486321", "endSection": "abstract"}]}
{"body": "What is the main role of Ctf4 in dna replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11287619", "http://www.ncbi.nlm.nih.gov/pubmed/24255107", "http://www.ncbi.nlm.nih.gov/pubmed/20381454", "http://www.ncbi.nlm.nih.gov/pubmed/19805216", "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "http://www.ncbi.nlm.nih.gov/pubmed/12455694", "http://www.ncbi.nlm.nih.gov/pubmed/23334284", "http://www.ncbi.nlm.nih.gov/pubmed/19430531", "http://www.ncbi.nlm.nih.gov/pubmed/9199353", "http://www.ncbi.nlm.nih.gov/pubmed/20980819", "http://www.ncbi.nlm.nih.gov/pubmed/24805245", "http://www.ncbi.nlm.nih.gov/pubmed/1448101", "http://www.ncbi.nlm.nih.gov/pubmed/16962805", "http://www.ncbi.nlm.nih.gov/pubmed/19496828", "http://www.ncbi.nlm.nih.gov/pubmed/19661920", "http://www.ncbi.nlm.nih.gov/pubmed/20089864", "http://www.ncbi.nlm.nih.gov/pubmed/19910927", "http://www.ncbi.nlm.nih.gov/pubmed/15226378", "http://www.ncbi.nlm.nih.gov/pubmed/14742710", "http://www.ncbi.nlm.nih.gov/pubmed/21470422"], "ideal_answer": ["coupling MCM2-7 to replicative polymerases is an important feature of the regulation of chromosome replication in eukaryotes, and highlight a key role for Ctf4 in this processAnd-1/Ctf4 is therefore a new replication initiation factor that brings together the MCM2-7 helicase and the DNA pol alpha-primase complex, analogous to the linker between helicase and primase or helicase and polymerase that is seen in the bacterial replication machinery", "Ctf4 coordinates the progression of helicase and DNA polymerase alpha.  Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication. And-1/Ctf4 is therefore a new replication initiation factor that brings together the MCM2-7 helicase and the DNA pol alpha-primase complex, analogous to the linker between helicase and primase or helicase and polymerase that is seen in the bacterial replication machinery."], "exact_answer": ["Coordination of the progression of helicase and DNA polymerase alpha at the eukaryotic replication fork."], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045740", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006261", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006260", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004261", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006275", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008156"], "type": "factoid", "id": "530cf22aa177c6630c000004", "snippets": [{"offsetInBeginSection": 95, "offsetInEndSection": 351, "text": "In this report, interactions between human Ctf4 (hCtf4) and the replicative helicase containing the cell division cycle 45 (Cdc45)/minichromosome maintenance 2-7 (Mcm2-7)/Go, Ichi, Nii, and San (GINS) (CMG) proteins [human CMG (hCMG) complex] were examined", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255107", "endSection": "abstract"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1130, "text": "We demonstrate that the hCtf4-CMG complex contains a homodimeric hCtf4 and a monomeric hCMG complex and suggest that the homodimeric hCtf4 acts as a platform linking polymerase α to the hCMG complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255107", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Drosophila Ctf4 is essential for efficient DNA replication and normal cell cycle progression", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "title"}, {"offsetInBeginSection": 246, "offsetInEndSection": 392, "text": "The Ctf4 protein has been shown to be a central member of the replication fork and links the replicative MCM helicase and DNA polymerase α primase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 584, "text": " it has been implicated as a member of a complex that promotes replication fork stability, the Fork Protection Complex (FPC), and as being important for sister chromatid cohesion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 913, "text": "Drosophila Ctf4 is a conserved protein that interacts with members of the GINS complex, Mcm2, and Polymerase α primase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1173, "text": "Ctf4 remains a central player in DNA replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 1004, "offsetInEndSection": 1084, "text": "These data indicate that Ctf4p facilitates Mcm10p to promote the DNA replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20381454", "endSection": "abstract"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1050, "text": " hCtf4 plays an essential role in DNA replication and its ability to stimulate the replicative DNA polymerases ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089864", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 592, "text": "Our data indicate that a complex of the GINS and Ctf4 components of the RPC is crucial to couple MCM2-7 to DNA polymerase alpha", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661920", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1119, "text": "coupling MCM2-7 to replicative polymerases is an important feature of the regulation of chromosome replication in eukaryotes, and highlight a key role for Ctf4 in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661920", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Ctf4 coordinates the progression of helicase and DNA polymerase alpha", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19496828", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 433, "text": "We show that And-1/Ctf4 (Chromosome transmission fidelity 4) interacts with Mcm10, which associates with MCM2-7, and with the p180 subunit of DNA pol alpha", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "endSection": "abstract"}, {"offsetInBeginSection": 854, "offsetInEndSection": 1125, "text": "And-1/Ctf4 is therefore a new replication initiation factor that brings together the MCM2-7 helicase and the DNA pol alpha-primase complex, analogous to the linker between helicase and primase or helicase and polymerase that is seen in the bacterial replication machinery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "endSection": "title"}, {"offsetInBeginSection": 1082, "offsetInEndSection": 1131, "text": "Ctf4 remains a central player in DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Drosophila Ctf4 is essential for efficient DNA replication and normal cell cycle progression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Influence of the human cohesion establishment factor Ctf4/AND-1 on DNA replication.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Ctf4/AND-1 is a highly conserved gene product required for both DNA replication and the establishment of sister chromatid cohesion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089864", "endSection": "abstract"}, {"offsetInBeginSection": 130, "offsetInEndSection": 250, "text": "In this report, we examined the mechanism of action of human Ctf4 (hCtf4) in DNA replication both in vitro and in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089864", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1120, "text": "And-1/Ctf4 is therefore a new replication initiation factor that brings together the MCM2-7 helicase and the DNA pol alpha-primase complex, analogous to the linker between helicase and primase or helicase and polymerase that is seen in the bacterial replication machinery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761813", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 909, "text": "We show that cells lacking both Ctf4 and Mrc1 experience chronic activation of the DNA damage checkpoint during chromosome replication and do not complete the cell cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661920", "endSection": "abstract"}, {"offsetInBeginSection": 886, "offsetInEndSection": 1083, "text": "Using in vivo RNAi knockdown of CTF4 in Drosophila we show that Ctf4 is required for viability, S phase progression, sister chromatid cohesion, endoreplication, and coping with replication stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1480, "text": "We show that Ctf4 function is conserved and that Drosophila can be effectively used as a model to further probe the precise function of Ctf4 as a member of the replication fork and possible roles in development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Chromosome transmission fidelity 4 (Ctf4) is a conserved protein required for DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255107", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 626, "text": "Here we show that three proteins required for sister chromatid cohesion, Eco1, Ctf4, and Ctf18, are found at, and Ctf4 travels along chromosomes with, replication forks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962805", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "A key role for Ctf4 in coupling the MCM2-7 helicase to DNA polymerase alpha within the eukaryotic replisome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661920", "endSection": "title"}]}
{"body": "Which integrin genes are activated by the immune system in inflammatory bowel disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28067908"], "ideal_answer": ["ITGA4, ITGB8, ITGAL and ICAM1. In all four cases, the expression-increasing allele also increases disease risk."], "exact_answer": [["ITGA4"], ["ITGB8"], ["ITGAL"], ["ICAM1"]], "type": "list", "id": "5c596ad686df2b9174000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 1119, "text": "Genetic association studies have identified 215 risk loci for inflammatory bowel disease, thereby uncovering fundamental aspects of its molecular biology. We performed a genome-wide association study of 25,305 individuals and conducted a meta-analysis with published summary statistics, yielding a total sample size of 59,957 subjects. We identified 25 new susceptibility loci, 3 of which contain integrin genes that encode proteins in pathways that have been identified as important therapeutic targets in inflammatory bowel disease. The associated variants are correlated with expression changes in response to immune stimulus at two of these genes (ITGA4 and ITGB8) and at previously implicated loci (ITGAL and ICAM1). In all four cases, the expression-increasing allele also increases disease risk. We also identified likely causal missense variants in a gene implicated in primary immune deficiency, PLCG2, and a negative regulator of inflammation, SLAMF8. Our results demonstrate that new associations at common variants continue to identify genes relevant to therapeutic target identification and prioritization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067908", "endSection": "abstract"}, {"offsetInBeginSection": 535, "offsetInEndSection": 721, "text": "The associated variants are correlated with expression changes in response to immune stimulus at two of these genes (ITGA4 and ITGB8) and at previously implicated loci (ITGAL and ICAM1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067908", "endSection": "abstract"}]}
{"body": "List scales that are used for scoring of patients with spinal metastasis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24212518", "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "http://www.ncbi.nlm.nih.gov/pubmed/24120144", "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "http://www.ncbi.nlm.nih.gov/pubmed/27584676", "http://www.ncbi.nlm.nih.gov/pubmed/27080411", "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "http://www.ncbi.nlm.nih.gov/pubmed/18787846", "http://www.ncbi.nlm.nih.gov/pubmed/26602195", "http://www.ncbi.nlm.nih.gov/pubmed/27018903", "http://www.ncbi.nlm.nih.gov/pubmed/25869337", "http://www.ncbi.nlm.nih.gov/pubmed/25085251"], "ideal_answer": ["Tokuhashi, Tomita, Bauer, and Oswestry scores are used for survival prediction of patients with spinal metastases."], "exact_answer": [["Tokuhashi"], ["Tomita"], ["Bauer"], ["Oswestry"]], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009362"], "type": "list", "id": "589a245878275d0c4a000025", "snippets": [{"offsetInBeginSection": 556, "offsetInEndSection": 682, "text": "METHODS: Outcomes of surgery, prognostic factors for survival, and relevance of Tomita and Tokuhashi scores were investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "PURPOSE: To assess variability in the use of Tomita and modified Bauer scores in spine metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25869337", "endSection": "abstract"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1213, "text": "Only the Tomita scoring system was shown to be an independent prognostic factor for overall survival. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "endSection": "abstract"}, {"offsetInBeginSection": 1359, "offsetInEndSection": 1462, "text": ".CONCLUSION: The Tomita scoring system represents a practicable and highly predictive prognostic tool. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "title"}, {"offsetInBeginSection": 95, "offsetInEndSection": 276, "text": "We also aimed to evaluate the validity of the prognostic scores in the Tomita and Tokuhashi systems and discuss several aspects to improve the predictive accuracy of these systems. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "abstract"}, {"offsetInBeginSection": 1527, "offsetInEndSection": 1612, "text": "CONCLUSIONS: Tomita scores more accurately predicted survival than Tokuhashi scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "title"}, {"offsetInBeginSection": 103, "offsetInEndSection": 215, "text": " It is for this reason that scoring systems, such as the modified Tokuhashi and Tomita scores, have been created", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "abstract"}, {"offsetInBeginSection": 1417, "offsetInEndSection": 1497, "text": "The modified Tokuhashi score had better accuracy in determining actual survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 316, "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 2366, "offsetInEndSection": 2491, "text": "All four scoring systems could be used to prognosticate these patients. The modified Tokuhashi score is the best in doing so.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1399, "text": "Primary tumor type and Tokuhashi score independently predicted survival in patients with spinal metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "endSection": "abstract"}, {"offsetInBeginSection": 1586, "offsetInEndSection": 1710, "text": " Primary tumor type and Tokuhashi scoring independently predicted survival in patients with spinal metastases after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1133, "text": "A predictive score was then developed and compared against that of the modified Bauer score alone in terms of prognosticating 1-year survival after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "endSection": "abstract"}, {"offsetInBeginSection": 2301, "offsetInEndSection": 2456, "text": "Our predictive score performed better than the modified Bauer alone and may be used to predict survival after surgical intervention for metastatic disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 704, "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).To investigate the accuracy of these scoring systems in predicting survival and to identify prognostic factors for survival of the patients with spinal metastases from NPC.Retrospective analysis of the patients with spinal metastases from NPC who were treated in our institution.The study included 87 patients with spinal metastases from NPC.The primary outcome measure was the survival time of these patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 2083, "offsetInEndSection": 2267, "text": "Predictive value of survival by modified Tokuhashi score was the highest among all four scoring systems.Patients with spinal metastases from NPC have relatively good survival prognosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 1748, "offsetInEndSection": 1994, "text": "The data of the present study emphasize that the original Bauer score and a modified Bauer score without scoring for pathologic fracture seem to be practicable and highly predictive preoperative scoring systems for patients with spinal metastases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18787846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 423, "text": "A retrospective study of 180 patients with lung cancer spinal metastases, wherein prognostic score-predicted survival was compared with actual survival.To evaluate and compare the accuracy of prognostic scoring systems in lung cancer spinal metastases.The modified Tokuhashi, Tomita, modified Bauer, and Oswestry scores are currently used to guide decisions regarding operative treatment of patients with spinal metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27018903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "To evaluate the predictive values of Tokuhashi score, revised Tokuhashi score and Tomita score systems for life expectancy and treatment options in patients with spinal metastasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "title"}, {"offsetInBeginSection": 1789, "offsetInEndSection": 1975, "text": "The combination of Tokuhashi score and Tomita score may be applied to better predict postoperative survival prognosis and guide the surgical options for patients with spinal metastasis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 441, "text": "reported a composite model taking into account a modified Bauer score, preoperative albumin, and ambulatory status of patients with spinal metastasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080411", "endSection": "abstract"}]}
{"body": "Which viruses are best known to cause myocarditis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18039618", "http://www.ncbi.nlm.nih.gov/pubmed/18277927", "http://www.ncbi.nlm.nih.gov/pubmed/2641165", "http://www.ncbi.nlm.nih.gov/pubmed/14993139", "http://www.ncbi.nlm.nih.gov/pubmed/3889351", "http://www.ncbi.nlm.nih.gov/pubmed/8199011"], "ideal_answer": ["The most frequent viruses causing myocarditis are Enterovirus, Adenovirus and Coxsackie B viruses."], "exact_answer": [["Enterovirus"], ["Adenovirus"], ["Coxsackie B virus"]], "type": "list", "id": "517a8c918ed59a060a000043", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 183, "text": "Enteroviruses (EV) are an important cause of neonatal disease including hepatitis, meningoencephalitis, and myocarditis that can lead to death or severe long-term sequelae", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18277927", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 147, "text": "Enteroviruses have been considered to be the most common cause of acute myocarditis and possible consequence of dilated cardiomyopathy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18039618", "endSection": "sections.0"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1116, "text": "n our study the adenovirus genome was found to be the most frequent virus genome in explanted heart tissues.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18039618", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3889351", "endSection": "sections.0"}]}
{"body": "Which are the common symptoms of Cushing's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24062268", "http://www.ncbi.nlm.nih.gov/pubmed/17322955"], "ideal_answer": ["Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension."], "exact_answer": [["weight gain"], ["growth retardation"], ["hirsutism"], ["obesity"], ["striae"], ["acne"], ["hypertension"]], "type": "list", "id": "571f3b320fd6f91b68000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062268", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 332, "text": "This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17322955", "endSection": "abstract"}]}
{"body": "List symptoms of Meigs' Syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24962423", "http://www.ncbi.nlm.nih.gov/pubmed/23328144", "http://www.ncbi.nlm.nih.gov/pubmed/25469326", "http://www.ncbi.nlm.nih.gov/pubmed/24490014", "http://www.ncbi.nlm.nih.gov/pubmed/26046039"], "ideal_answer": ["Meigs' syndrome is a benign ovarian tumor associated with ascites and pleural effusion."], "exact_answer": [["benign ovarian tumor"], ["ascites"], ["pleural effusion"]], "type": "list", "id": "56be0a18ef6e394741000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Meigs' syndrome is a benign ovarian tumor associated with ascites and pleural effusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046039", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 1030, "text": "Although postmenopausal women with ovarian tumor, ascites, pleural effusion, and elevation of CA-125 levels probably have malignant ovarian tumors, Meigs' syndrome must be considered in the differential diagnosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "BACKGROUND: The Demons-Meigs syndrome should usually be evoked in case of presence of a typical triad: abdominopelvic mass, ascites and hydrothorax. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25469326", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1109, "text": "CONCLUSION: Meigs' syndrome should be considered at the differential diagnosis for a patient with pelvic mass, pleural effusion and ascites with normal cytology, increased CA125 levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "BACKGROUND: The Meigs' syndrome is a rare but well-known syndrome defined as the triad of benign solid ovarian tumor, ascites, and pleural effusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Ovarian mass, pleural effusion, and ascites: revisiting Meigs syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23328144", "endSection": "title"}, {"offsetInBeginSection": 198, "offsetInEndSection": 306, "text": "When benign ovarian fibroma is associated with ascites and/or pleural effusion it is termed Meigs syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23328144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Ovarian mass, pleural effusion, and ascites: revisiting Meigs syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23328144", "endSection": "title"}]}
{"body": "List interaction partners for the protein GATA1.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16339652", "http://www.ncbi.nlm.nih.gov/pubmed/21532337", "http://www.ncbi.nlm.nih.gov/pubmed/17108004", "http://www.ncbi.nlm.nih.gov/pubmed/18844071", "http://www.ncbi.nlm.nih.gov/pubmed/12032775", "http://www.ncbi.nlm.nih.gov/pubmed/20959602", "http://www.ncbi.nlm.nih.gov/pubmed/15542823", "http://www.ncbi.nlm.nih.gov/pubmed/15920471"], "ideal_answer": ["GATA-1 interact with factor Gfi-1b, the repressive MeCP1 complex, the chromatin remodeling ACF/WCRF complex, FOG-1, TAL-1, Ldb-1 and LMO2-C.", "GATA1 interacts with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. Ldb1 is a known partners of GATA1. LMO2-C can bind endogenous GATA1. Novel transcription factor binding partners for PIAS3 include GATA1. Combinatorial interactions occurre between RUNX1 and its coregulator GATA1. Ski interacts with GATA1. GATA-1 interacts with multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1."], "exact_answer": [["Gfi-1b"], ["MeCP1", "MeCP1 complex"], ["ACF/WCRF complex"], ["FOG-1"], ["TAL-1"], ["Ldb1", "Ldb-1"], ["LMO2-C"], ["PIAS3"], ["RUNX1"], ["Ski"], ["EKLF"], ["SP1"], ["CBP/p300"], ["PU.1"]], "concepts": ["http://www.uniprot.org/uniprot/GATA1_RAT", "http://www.uniprot.org/uniprot/GATA1_MOUSE", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025941", "http://www.uniprot.org/uniprot/GATA1_ARATH", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054730", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060066", "http://www.uniprot.org/uniprot/GATA1_CHICK", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050982", "http://www.uniprot.org/uniprot/GATA1_HUMAN"], "type": "list", "id": "52f89fd32059c6d71c000051", "snippets": [{"offsetInBeginSection": 752, "offsetInEndSection": 1519, "text": "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. We also provide evidence that distinct GATA-1 complexes are associated with specific GATA-1 functions in erythroid differentiation, for example, GATA-1/Gfi-1b with the suppression of cell proliferation and GATA-1/FOG-1/MeCP1 with the repression of other hematopoietic transcription programs. We next applied the biotinylation tag to Ldb-1, a known partner of GATA-1, and characterized a number of novel interaction partners that are essential in erythroid development, in particular, Eto-2, Lmo4, and CdK9. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 604, "text": "Endogenous GATA1 and LDB1 proteins were confirmed to bind to LMO2-C by MBP pull down analysis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18844071", "endSection": "abstract"}, {"offsetInBeginSection": 948, "offsetInEndSection": 1053, "text": "LMO2-C can bind endogenous GATA1 and LDB1 protein in K562 cells and down regulates the expression of GPA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18844071", "endSection": "abstract"}, {"offsetInBeginSection": 483, "offsetInEndSection": 587, "text": "We identify novel transcription factor binding partners for PIAS3 including ETS, EGR1, NR1I2, and GATA1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21532337", "endSection": "abstract"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1301, "text": "At other differentiation stages, additional combinatorial interactions occurred between RUNX1 and its coregulators, GATA1 and ETS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20959602", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Ldb1, a ubiquitously expressed LIM domain binding protein, is essential in a number of tissues during development. It interacts with Gata1, Tal1, E2A and Lmo2 to form a transcription factor complex regulating late erythroid genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17108004", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 850, "text": "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. Importantly, we show that FOG-1 mediates GATA-1 interactions with the MeCP1 complex, thus providing an explanation for the overlapping functions of these two factors in erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920471", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 868, "text": "Here we show that Ski interacts with GATA1, a transcription factor essential in erythropoiesis. Using a Ski mutant deficient in GATA1 binding, we show that this Ski-GATA1 interaction is critical for Ski's ability to repress GATA1-mediated transcription and block erythroid differentiation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15542823", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 432, "text": "The zinc finger transcription factor GATA-1, a central mediator of erythroid gene expression, interacts with multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12032775", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 1155, "text": "tudies involving point mutants of GATA-1 have shown that a direct physical interaction between GATA-1 and FOG-1 is essential for normal human erythroid and megakaryocyte maturation in vivo. In addition, evidence has emerged that physical interaction between GATA-1 and the myeloid/lymphoid specific factor PU.1, an oncogene implicated in murine erythroleukemia, acts to functionally cross-antagonize one another. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12032775", "endSection": "abstract"}]}
{"body": "What is Mondor's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1562972", "http://www.ncbi.nlm.nih.gov/pubmed/21855258", "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "http://www.ncbi.nlm.nih.gov/pubmed/25960806", "http://www.ncbi.nlm.nih.gov/pubmed/22421473", "http://www.ncbi.nlm.nih.gov/pubmed/19608071", "http://www.ncbi.nlm.nih.gov/pubmed/6613471", "http://www.ncbi.nlm.nih.gov/pubmed/18385566", "http://www.ncbi.nlm.nih.gov/pubmed/8885560", "http://www.ncbi.nlm.nih.gov/pubmed/21450061", "http://www.ncbi.nlm.nih.gov/pubmed/26803533", "http://www.ncbi.nlm.nih.gov/pubmed/22377612", "http://www.ncbi.nlm.nih.gov/pubmed/24867818", "http://www.ncbi.nlm.nih.gov/pubmed/25530373", "http://www.ncbi.nlm.nih.gov/pubmed/11771217", "http://www.ncbi.nlm.nih.gov/pubmed/23674771", "http://www.ncbi.nlm.nih.gov/pubmed/26971966", "http://www.ncbi.nlm.nih.gov/pubmed/10630059", "http://www.ncbi.nlm.nih.gov/pubmed/22414457", "http://www.ncbi.nlm.nih.gov/pubmed/20579824", "http://www.ncbi.nlm.nih.gov/pubmed/7243138", "http://www.ncbi.nlm.nih.gov/pubmed/25923155", "http://www.ncbi.nlm.nih.gov/pubmed/19629969", "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "http://www.ncbi.nlm.nih.gov/pubmed/15906794"], "ideal_answer": ["Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall and genital area."], "type": "summary", "id": "589a246778275d0c4a00002f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "INTRODUCTION: Mondor's disease is a rare superficial thrombophlebitis, historically involving the thoracic venous system of women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26971966", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Mondor's disease is a rare condition characterized by a superficial thrombophlebitis that can occur in the thoracoabdominal and genital areas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1680, "text": "CONCLUSION: Penile Mondor disease is a rare complication that can be successfully treated with medical therapy and conservative approach. Our series showed that penile Mondor's disease does not lead to permanent deformation of the penis or erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25530373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Thrombophlebitis of the thoracoepigastric system of veins is a benign disease and, despite its localized involvement and presentation, the condition is known as Mondor disease (MD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19608071", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 685, "text": "Though penile Mondor's disease involving the dorsal vein of the penis has been reported by many authors, we report a peculiar case of penile Mondor's disease in a 26-year-old sexually active man with thrombophlebitis of the circumflex vein of the penis with sparing of the dorsal vein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24867818", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 348, "text": "Mondor's disease of the penis is an uncommon condition, which usually involves the superficial dorsal veins, it was first described by Braun-Falco in 1955.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15906794", "endSection": "abstract"}, {"offsetInBeginSection": 297, "offsetInEndSection": 404, "text": "Penile Mondor's disease is rare disease that's characterized by thrombosis in the dorsal vein of the penis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18385566", "endSection": "abstract"}]}
{"body": "What is caused by SCUBE3 loss of function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33308444"], "ideal_answer": ["SCUBE3 loss-of-function causes a recognizable recessive developmental disorder due to defective bone morphogenetic protein signaling.", "SCUBE3 is a BMP2/BMP4 co-receptor. It is responsible for the development of bone and teeth. When it is not functioning properly, it inhibits the growth and development of these tissues.", "SCUBE3 loss-of-function results in a human disease caused by defective function of a member of the SCUBE family that is associated with a previously unrecognized syndromic disorder. The disorder is characterized by reduced growth, skeletal features, distinctive craniofacial appearance, and dental anomalies. It is also associated with dysregulating bone morphogenetic protein signaling."], "type": "summary", "id": "61f86db9882a024a10000045", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "SCUBE3 loss-of-function causes a recognizable recessive developmental disorder due to defective bone morphogenetic protein signaling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308444", "endSection": "title"}, {"offsetInBeginSection": 206, "offsetInEndSection": 1481, "text": "Here we report that bi-allelic inactivating variants in SCUBE3 have pleiotropic consequences on development and cause a previously unrecognized syndromic disorder. Eighteen affected individuals from nine unrelated families showed a consistent phenotype characterized by reduced growth, skeletal features, distinctive craniofacial appearance, and dental anomalies. In vitro functional validation studies demonstrated a variable impact of disease-causing variants on transcript processing, protein secretion and function, and their dysregulating effect on bone morphogenetic protein (BMP) signaling. We show that SCUBE3 acts as a BMP2/BMP4 co-receptor, recruits the BMP receptor complexes into raft microdomains, and positively modulates signaling possibly by augmenting the specific interactions between BMPs and BMP type I receptors. Scube3-/- mice showed craniofacial and dental defects, reduced body size, and defective endochondral bone growth due to impaired BMP-mediated chondrogenesis and osteogenesis, recapitulating the human disorder. Our findings identify a human disease caused by defective function of a member of the SCUBE family, and link SCUBE3 to processes controlling growth, morphogenesis, and bone and teeth development through modulation of BMP signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308444", "endSection": "abstract"}]}
{"body": "Where is the protein CLIC1 localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21055175", "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "http://www.ncbi.nlm.nih.gov/pubmed/9880541"], "triples": [{"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q5E9B7", "o": "http://linkedlifedata.com/resource/#_51354539423700E"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_51354539423700E", "o": "CLIC1"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_51354539423700C", "o": "Chloride intracellular channel protein 1"}, {"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q95MF9", "o": "http://linkedlifedata.com/resource/#_5139354D463900A"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5139354D463900A", "o": "CLIC1"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_5139354D4639009", "o": "Chloride intracellular channel protein 1"}], "ideal_answer": ["CLIC1 is an intracellular chloride ion channel that is localized both to the nucleus and to the cytolasm."], "concepts": ["http://www.uniprot.org/uniprot/CLIC1_MOUSE", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008104", "http://www.uniprot.org/uniprot/CLIC1_RAT", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051234", "http://www.uniprot.org/uniprot/CLIC1_PIG", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051179", "http://www.uniprot.org/uniprot/CLIC1_HUMAN", "http://www.uniprot.org/uniprot/CLIC1_RABIT", "http://www.uniprot.org/uniprot/CLIC1_BOVIN"], "type": "summary", "id": "53319916d6d3ac6a3400003f", "snippets": [{"offsetInBeginSection": 611, "offsetInEndSection": 706, "text": "CLIC1 expression was obtained in the cytoplasm and plasma membrane of cells in both cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21055175", "endSection": "abstract"}, {"offsetInBeginSection": 641, "offsetInEndSection": 686, "text": "CLIC1, an intracellular chloride ion channel,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "endSection": "abstract"}, {"offsetInBeginSection": 612, "offsetInEndSection": 678, "text": "Like NCC27/CLIC1, CLIC3 is predominantly localized in the nucleus ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9880541", "endSection": "abstract"}, {"offsetInBeginSection": 1270, "offsetInEndSection": 1357, "text": "the nuclear localization pattern of CLIC1 was remarkably changed by insulin stimulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "endSection": "abstract"}]}
{"body": "What is the definition of trichotillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35118122"], "ideal_answer": ["Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body."], "type": "summary", "id": "6414c1ae690f196b51000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35118122", "endSection": "abstract"}]}
{"body": "What are the birth defects associated with Zika-virus infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27032458", "http://www.ncbi.nlm.nih.gov/pubmed/27293547", "http://www.ncbi.nlm.nih.gov/pubmed/27052792", "http://www.ncbi.nlm.nih.gov/pubmed/27366760", "http://www.ncbi.nlm.nih.gov/pubmed/27279226", "http://www.ncbi.nlm.nih.gov/pubmed/27032431", "http://www.ncbi.nlm.nih.gov/pubmed/27143174", "http://www.ncbi.nlm.nih.gov/pubmed/27617189", "http://www.ncbi.nlm.nih.gov/pubmed/27366586", "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "http://www.ncbi.nlm.nih.gov/pubmed/27345865", "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "http://www.ncbi.nlm.nih.gov/pubmed/27009036"], "ideal_answer": ["Although the full spectrum of adverse reproductive outcomes caused by Zika virus infection is not yet determined, a distinctive phenotype-the congenital Zika syndrome-has emerged. Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects."], "type": "summary", "id": "58a989571978bbde22000002", "snippets": [{"offsetInBeginSection": 768, "offsetInEndSection": 1090, "text": "the first time after the discovery of ZIKV, the Brazilian scientists are studying the possibility for the virus to cause severe congenital infection related to microcephaly and serious birth defects due to the time-spatial coincidence of the alarming increase of newborns with microcephaly and the Brazilian ZIKV epidemic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143174", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 286, "text": " Although a causal relationship between Zika infection during pregnancy and microcephaly is strongly suspected, such a connection has not yet been scientifically proven. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052792", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 302, "text": "a convincing association between Zika virus infection during pregnancy and birth defects, like microcephaly, among some of the newborns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27032431", "endSection": "abstract"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1039, "text": "counseling pregnant women on the risks of fetal microcephaly and other birth defects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27032458", "endSection": "abstract"}, {"offsetInBeginSection": 576, "offsetInEndSection": 711, "text": "evidence suggests that congenital Zika virus infection is associated with microcephaly and other adverse pregnancy and infant outcomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009036", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 885, "text": "the virus has been linked to congenital malformations, including microcephaly and other severe neurological diseases, such as Guillain-Barré syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27279226", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 380, "text": " severe birth defects, such as microcephaly, have been linked to infection during early pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293547", "endSection": "abstract"}, {"offsetInBeginSection": 31, "offsetInEndSection": 290, "text": "n can be prenatally passed from a pregnant woman to her fetus. There is sufficient evidence to conclude that intrauterine Zika virus infection is a cause of microcephaly and serious brain anomalies, but the full spectrum of anomalies has not been delineated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "endSection": "abstract"}, {"offsetInBeginSection": 1699, "offsetInEndSection": 1878, "text": "Although the full spectrum of adverse reproductive outcomes caused by Zika virus infection is not yet determined, a distinctive phenotype-the congenital Zika syndrome-has emerged.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The current Zika virus (ZIKV) outbreak is associated with high numbers of human congenital birth defects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345865", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 427, "text": "However, ZIKV infection in early pregnancy has been associated with severe birth defects, including microcephaly and other developmental issues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Zika virus (ZIKV) infection is a new emerging threat around the globe which might be responsible for microcephaly and Guillain-Barre syndrome in the infants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366760", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 282, "text": "Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "endSection": "abstract"}]}
{"body": "What is IDD in relation to organ transplantation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28027062", "http://www.ncbi.nlm.nih.gov/pubmed/32633023", "http://www.ncbi.nlm.nih.gov/pubmed/28030433"], "ideal_answer": ["Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death", "Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to death", "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient."], "type": "summary", "id": "623648723a8413c6530000af", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 173, "text": "Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to death", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 358, "text": "Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 345, "text": " organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "PURPOSE OF REVIEW: Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 340, "text": "ent organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 167, "text": ": Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "PURPOSE OF REVIEW: Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 437, "text": "ent organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death.RECENT FINDINGS: A protocol for IDD was developed at Rhode Island Hospital and", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062", "endSection": "abstract"}]}
